
Lorglumide sodium salt
CAS No. 1021868-76-7
Lorglumide sodium salt( CR-1409 sodium salt )
Catalog No. M26280 CAS No. 1021868-76-7
Lorglumide sodium salt is a potent cholecystokinin (CCK) receptor antagonist.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 42 | Get Quote |
![]() ![]() |
10MG | 65 | Get Quote |
![]() ![]() |
25MG | 107 | Get Quote |
![]() ![]() |
100MG | Get Quote | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameLorglumide sodium salt
-
NoteResearch use only, not for human use.
-
Brief DescriptionLorglumide sodium salt is a potent cholecystokinin (CCK) receptor antagonist.
-
DescriptionLorglumide sodium salt is a potent cholecystokinin (CCK) receptor antagonist.
-
In Vitro——
-
In Vivo——
-
SynonymsCR-1409 sodium salt
-
PathwayGPCR/G Protein
-
TargetCholecystokinin Receptor
-
RecptorPEGs
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1021868-76-7
-
Formula Weight481.39
-
Molecular FormulaC22H31Cl2N2NaO4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (207.73 mM)
-
SMILESCCCCCN(CCCCC)C(=O)C(CCC(=O)O[Na])NC(=O)c1ccc(Cl)c(Cl)c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562
molnova catalog



related products
-
N-Cbz-DL-tryptophan
N-Cbz-DL-tryptophan is a cholecystokinin receptor antagonist, abolished the response of the isolated heart to CCK-8.
-
Ceruletide
Ceruletide is a potent agonist of cholecystokinin receptor and it also is a safe and effective cholecystokinetic agent. It has a direct spasmogenic effect on the gallbladder muscle and bile ducts.Ceruletide is same as biologically and chemically to the human gastrointestinal hormones cholecystokinin-pancreozymin (CCK) and gastrin II.
-
JNJ-26070109
A novel, potent, selective orally active CCK-2 receptor antagonist with pKi of 8.49 for hCCK2.